Overview

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Status:
Not yet recruiting

Trial end date:
2028-02-15

Target enrollment:

Participant gender:

Summary

Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of furmonertinib at 2 dose levels (160 mg once daily [QD] and 240 mg QD) compared to platinum-based chemotherapy in previously untreated patients with locally advanced or metastatic non-squamous NSCLC with EGFR exon 20 insertion mutations. A target of approximately 375 patients will be randomized in a 1:1:1 ratio to treatment with furmonertinib 240 mg QD, furmonertinib 160 mg QD, or platinum-based chemotherapy.

Phase:

Phase 3

Details

Lead Sponsor:

ArriVent BioPharma, Inc.

Collaborator:

Allist Pharmaceuticals, Inc.

Treatments:

Aflutinib